www.npca.org.uk
e-mail:npca@rcseng.ac.uk

NPCA
National Prostate Cancer Audit

RCS ADVANCING SURGICAL STANDARDS

Version 2.1, 17th December 2014

Summary of clinical data items for collection from 1st April 2014 in England and Wales. The data set is arranged into three sections. The first section will be collected from all men with newly diagnosed prostate cancer, the second focuses on men who have undergone radical prostatectomy and the third concerns all men where external beam radiation therapy or brachytherapy, with or without hormone therapy, is planned.

NPCA MINIMUM DATA SET 1: To be completed for all men with newly diagnosed prostate cancer. All data items to be completed at meeting (s) of the multidisciplinary team (MDT) except 'Planned prostate cancer treatment agreed with the patient'.

Patient Characteristics

1. Date of diagnosis (clinically agreed) --/--/----

2. Symptoms prior to diagnosis

- ☐ None
- ☐ Lower Urinary Tract Symptoms (LUTS)
- ☐ Symptoms possibly linked to metastasis (e.g. pain)
- ☐ General symptoms (e.g. weight loss, lethargy)
- ☐ Not known

3. Performance status (adult)

- ☐ Able to carry out all normal activity without restriction.
- ☐ Restricted in physically strenuous activity, but able to walk and do light work.
- ☐ Able to walk and capable of all self care, but unable to carry out any work. Up and about more than 50% of waking hours.
- ☐ Capable of only limited self care, confined to bed or chair more than 50% of waking hours.
- ☐ Completely disabled. Cannot carry out any self care. Totally confined to bed or chair.
- ☐ Not recorded

4. ASA score – prostate (collect from ALL patients whether surgery is planned or not)

- ☐ A normal healthy patient.
- ☐ A patient with mild systemic disease.
- ☐ A patient with severe systemic disease that limits function but is not incapacitating.
- ☐ A patient with severe systemic disease that is a constant threat to life.
- ☐ A moribund patient.

5. Source of referral for out-patients

- ☐ Following an emergency admission.
- ☐ Following an accident and emergency attendance.
- ☐ Referral from a general medical practitioner.
- ☐ Referral from a consultant other than in an accident and emergency department.
- ☐ Other

6. PSA (diagnosis) _____ (ng/ml)

7. Prostate biopsy technique

- ☐ No Biopsy done
- ☐ Transrectal sampling biopsy
- ☐ Transrectal saturation biopsy
- ☐ Perineal sampling biopsy
- ☐ Perineal Template Mapping biopsy
- ☐ Other
- ☐ Not known

Gleason Score of Biopsy

1. Gleason grade (primary) _____ **2. Gleason grade (secondary)** _____

3. Gleason grade (tertiary) _____

Magnetic Resonance Imaging of Prostate

1. Multiparametric MRI performed

- ☐ No
- ☐ Before biopsy
- ☐ After biopsy
- ☐ Not known

Final Pre-Treatment Tumour Characteristics

1. T category (final pre-treatment) _____ **2. N category (final pre-treatment)** _____

3. M category (final pre-treatment) _____

4. Perineural invasion

- ☐ Yes
- ☐ No
- ☐ Not Assessable

5. Number of positive cores _____ **6. Total number of cores** _____

7. Greatest percentage of cancer in single most involved core _____ **(%)**

Treatment

1. Specialist referral appointments

- ☐ Urologist only
- ☐ Oncologist only
- ☐ Urologist and oncologist separately
- ☐ Urologist and oncologist in joint specialist MDT clinic setting
- ☐ None of the above
- ☐ Not known

2. Planned prostate cancer treatment agreed with the patient

- ☐ Watchful waiting
- ☐ Active surveillance
- ☐ Radical Prostatectomy
- ☐ Transurethral Resection of Prostate (TURP)
- ☐ Bilateral Orchidectomy
- ☐ Cryotherapy
- ☐ High Intensity Focused Ultrasound (HIFU)
- ☐ Focal Therapy (any modality)
- ☐ Radical External Beam Radiotherapy
- ☐ Low Dose Rate Brachytherapy
- ☐ High Dose Rate Brachytherapy
- ☐ Continuous Androgen Deprivation Therapy
- ☐ Intermittent Androgen Deprivation Therapy
- ☐ Neoadjuvant hormone therapy
- ☐ Adjuvant hormone therapy
- ☐ Chemotherapy
- ☐ Palliative Radiotherapy
- ☐ Specialist palliative care
- ☐ Other – active

NPCA MINIMUM DATA SET 2: Data items to be collected for all men who have undergone a radical prostatectomy. To be completed at the MDT meeting following radical surgery.

Radical prostatectomy details

1. Organisation site code - cancer_____ **2. Consultant code (treatment)**_____

3. Type of radical prostatectomy (actual)

- ☐ Open prostatectomy
- ☐ Robotic prostatectomy
- ☐ Laparoscopic prostatectomy
- ☐ Not known

4. Procedure date --/--/----

5. Procedure - nerve sparing

- ☐ Bilateral
- ☐ Unilateral
- ☐ None

6. T category (pathological) _____ **7. N category (pathological)** _____

8. Organ confined

- ☐ Yes
- ☐ No
- ☐ Not Applicable

9. Seminal vesicles invasion

- ☐ Yes
- ☐ No
- ☐ Not Applicable

10. Radical prostatectomy margin status

- ☐ Negative Margins
- ☐ Positive margins < 3 mm in length
- ☐ Positive margins ≥ 3 mm in length
- ☐ Positive margins, length unknown
- ☐ Not known

11. Lymphadenectomy

- ☐ Yes
- ☐ No

NPCA MINIMUM DATA SET 3: Data items to be collected for all men for whom external beam radiation or brachytherapy is planned with or without androgen deprivation therapy. To be completed before actual treatment takes place.

Radiotherapy details

1. Planned radiotherapy intent (prostate)

- ☐ Primary radical intent
- ☐ Adjuvant
- ☐ Palliative
- ☐ Other
- ☐ Not known

2. Planned radiotherapy type

- ☐ 3D conformal
- ☐ IMRT
- ☐ Arcing IMRT
- ☐ SBRT
- ☐ Other
- ☐ Not known

3. Planned type of image-guidance for external beam radiotherapy

- ☐ Cone beam CT
- ☐ Fiducial markers
- ☐ Combined cone beam CT with fiducial markers
- ☐ KV imaging
- ☐ Other
- ☐ Not known

4. Planned radiotherapy field

- ☐ Prostate
- ☐ Prostate and seminal vesicles
- ☐ Prostate, seminal vesicles and lymph nodes
- ☐ Prostate Bed
- ☐ Prostate Bed and lymph nodes
- ☐ Other (eg spine, leg)
- ☐ Not known

Brachytherapy details

1. Planned brachytherapy type

- ☐ LDR monotherapy
- ☐ LDR boost
- ☐ HDR monotherapy
- ☐ HDR boost
- ☐ Not known

2. Planned brachytherapy total dose _____**(Gy)** **3. Planned brachytherapy total fractions**_____**(#)**

Androgen deprivation therapy details in men due to undergo external beam radiation therapy

1. Planned duration of neoadjuvant androgen deprivation therapy

- ☐ None
- ☐ Between 2 and 6 months
- ☐ Longer than 6 months
- ☐ Not known

2. Planned total duration of adjuvant androgen deprivation therapy

- ☐ None
- ☐ 6 months
- ☐ 18 months
- ☐ 2 years
- ☐ 3 years
- ☐ Indefinite
- ☐ Other (eg intermittent)
- ☐ Not known